Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.68Last Year’s EPS
0.41Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 18, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Positive
Penumbra demonstrated robust growth and profitability in its U.S. thrombectomy business, driven by product innovation and strategic expansion. However, international revenue challenges, particularly in China, and costs associated with the exit from Immersive Healthcare slightly tempered overall performance. The overall sentiment is positive due to strong domestic growth and future strategic initiatives outweighing the international setbacks.Company Guidance
During the fourth quarter of 2024 conference call, Penumbra provided detailed guidance and metrics for the upcoming year. The company reported a Q4 2024 non-GAAP revenue of $321.3 million, marking a 12.9% year-over-year growth, with a gross margin of 67.4%, up by 170 basis points from the previous year. The U.S. thrombectomy business, a key growth driver, saw a 27.3% increase in Q4 sales, contributing to a full-year revenue of $1.2 billion, a 13.4% increase from 2023. International sales decreased by 9.4% due to a significant decline in China. The company also highlighted its expectation for 2025 revenue growth between 12% and 14%, with U.S. thrombectomy sales projected to grow by 19-20%. Looking ahead, Penumbra aims to achieve a gross margin over 70% by the end of 2026 and plans to expand its manufacturing capacity with a new facility in Costa Rica, enhancing its operational efficiencies.Strong Revenue Growth
Fourth quarter 2024 revenue reached $321.3 million, representing a year-over-year growth of 12.9% on an adjusted basis and 13% on a constant currency basis. Full year revenue increased 13.4% year-over-year to over $1.2 billion.
U.S. Thrombectomy Business Performance
U.S. thrombectomy sales increased 27.3% year-over-year to $180.6 million in Q4, with the U.S. VTE franchise delivering robust year-over-year revenue growth of 41%. The full year revenue for the U.S. thrombectomy business was $646.7 million, reflecting a 26.8% increase versus 2023.
Product Innovation and Expansion
Introduced 9 new products to the U.S. commercial market, including new CAVT products like Flash 2.0 and Lightning Bolt 12. Expanded CAVT's footprint into Europe and additional international geographies.
Profitability and Margin Expansion
Fourth quarter gross margin of 67.4% expanded 170 basis points over the prior year period. Operating income of $48.6 million or 15.1% of revenue increased 200 basis points over the prior year period. Generated $49.1 million in operating cash in Q4.
Future Growth Strategy
Signed a contract to build a manufacturing facility in Costa Rica to expand manufacturing capacity. Aimed to achieve a gross margin profile over 70% by the end of 2026, with operating margin expansion expected to outpace gross margin expansion.
---
PEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 18, 2025 | $271.14 | ― | ― |
| Oct 30, 2024 | $211.29 | $228.87 | +8.32% |
| Jul 30, 2024 | $173.09 | $167.09 | -3.47% |
| May 07, 2024 | $210.00 | $203.09 | -3.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Penumbra (PEN) report earnings?
Penumbra (PEN) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is Penumbra (PEN) earnings time?
Penumbra (PEN) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PEN EPS forecast?
PEN EPS forecast for the fiscal quarter 2025 (Q1) is 0.68.
---